Robert L. Eisner

A new method for the determination of aortic pulse wave velocity using cross-correlation on 2D PCMR velocity data

To evaluate the reproducibility of a new multisite axial pulse wave velocity (PWV) measurement technique that makes use of 2D PCMR data and cross‐correlation analysis.

Comparison of myocardial velocities obtained with magnetic resonance phase velocity mapping and tissue doppler imaging in normal subjects and patients with left ventricular dyssynchrony

To compare longitudinal myocardial velocity and time to peak longitudinal velocity obtained with magnetic resonance phase velocity mapping (MR‐PVM) and tissue Doppler imaging (TDI), and to assess the reproducibility of each method.

Three-directional myocardial phase-contrast tissue velocity MR imaging with navigator-echo gating: in vivo and in vitro study.

The study protocol was HIPAA compliant and institutional review board approved. Informed consent was obtained from all participants. The purpose of the study was to prospectively validate the capability of navigator-echo-gated phase-contrast magnetic resonance (MR) imaging for measurement of myocardial velocities in a phantom and to prospectively use the phase-contrast MR sequence to measure three-directional velocity in the myocardium in vivo in volunteers and in patients scheduled for cardiac resynchronization therapy. An excellent correlation between the measured velocity and the true phantom motion (R = 0.90 for longitudinal velocity, R = 0.93 for circumferential velocity) was observed. Myocardial velocities were successfully measured in 17 healthy volunteers (11 male, six female; mean age, 27.5 years +/- 6.5 [standard deviation]) and 28 patients with heart failure (18 male, 10 female; mean age, 63.9 years +/- 15.0). Velocity values were significantly lower in the patients than in the volunteers. The time to peak velocity in the lateral wall of the patients, as compared with that in the volunteers, was delayed. Phase-contrast MR imaging can be combined with navigator-echo gating to measure three-directional myocardial tissue velocities in vivo.

Comparison of single-photon emission computed tomographic (SPECT) myocardial perfusion imaging with thallium-201 and technetium-99m sestamibi in dogs

OBJECTIVES The purpose of the present study was to compare single-photon emission computed tomographic (SPECT) myocardial images of technetium-99m (Tc-99m) sestamibi and thallium-201 (Tl-201) isotopes in the same dog undergoing partial coronary occlusion during pharmacologic vasodilation. BACKGROUND To date, no controlled study has been reported comparing SPECT Tc-99m sestamibi with SPECT Tl-201 imaging during stress with anatomic and physiologic standards. METHODS Mongrel dogs were anesthetized with chloralose and instrumented to record left anterior descending coronary blood flow and aortic pressure. Partial coronary occlusion with a hydraulic cuff reduced coronary vascular conductance, which is equal to the coronary blood flow normalized to aortic pressure during peak vasodilation with intravenous adenosine. Each dog received 5 mCi of Tl-201, then 30 mCi of Tc-99m sestamibi during partial coronary occlusion at peak vasodilation. Tomographic myocardial imaging was performed in a 180 degrees anterior arc scan for 33.5 min, first with Tl-201, and later, without moving the dog, for 33.5 min with Tc-99m sestamibi. Postmortem staining defined the region underperfused because of its dependence on the artery that was partially occluded. RESULTS In seven dogs with moderate reduction in coronary blood flow, coronary vascular conductance decreased with partial coronary occlusion (47 +/- 12%) during Tl-201 imaging and (47 +/- 8%, p = NS) during Tc-99m sestamibi imaging. The underperfused region was 23.9 +/- 6.4% of total left ventricular mass. Counts in the defects were 39% higher (0.86 +/- 0.08 of normal counts) for Tc-99m sestamibi than for Tl-201 (0.64 +/- 0.09 of normal counts, p < 0.001), and the defect on SPECT Tc-99m sestamibi images occupied only a fraction (0.37 +/- 0.30) of the area of the defect on the Tl-201 images of the same dog. Bulls-eye displays constructed from the pathologic slices showed that the Tl-201 defect size was closer to the underperfused region of the left ventricular mass determined pathologically than was the Tc-99m sestamibi defect size. In four additional dogs a severe, near total coronary occlusion was created during Tl-201 and Tc-99m sestamibi administration. In these dogs, similar defect contrast (0.55 +/- 0.12 vs. 0.62 +/- 0.09, p = NS) and areas (0.18 +/- 0.07 vs. 0.18 +/- 0.11, p = NS) were observed with Tl-201 and Tc-99m sestamibi, respectively. CONCLUSIONS Tomographic myocardial imaging with Tc-99m sestamibi during moderately severe partial coronary occlusion underestimated the area of the defect relative to Tl-201 or to the pathologic reference standard in dogs. Defect contrast was sharper with tomographic myocardial Tl-201 than with tomographic myocardial Tc-99m sestamibi during moderately severe partial coronary occlusion.

Comparison of modalities to diagnose coronary artery disease

The purpose of this review is to compare several modalities available for detection of coronary artery disease (CAD). We compare the clinical history, rest/exercise electrocardiogram (ECG), rest/stress left ventricular (LV) function by radionuclide or echocardiographic methods, myocardial perfusion imaging (MPI) by single photon emission computed tomography (SPECT) or positron emission tomography (PET), contrast coronary angiography, magnetic resonance imaging (MRI), spectroscopy (MRS) and angiography (MRA), and ultrafast cine computed tomography (UFCT) to assess LV function, myocardial perfusion, and coronary calcification. We compare the modalities by answering six questions: (1) Does the modality provide unique clinical information? (2) What is the observer error? (3) What are sensitivities and specificities to detect CAD? (4) What patient selection criteria should be applied for each modality? (5) What incremental benefit is obtained from one modality versus another modality? and (6) Where do the modalities fit in the overall scheme of diagnostic testing for CAD? PET MPI appears to be the best noninvasive test for CAD, followed by SPECT thallium-201 and then dobutamine echocardiography. MRA and UFCT may soon play a larger role because they visualize the arteries. Contrast coronary angiography remains the gold standard despite its limitations. Exercise ECG is the least accurate test. The choice of tests critically depends on patient selection--based on clinical history, age, gender, and risk factors to estimate the pretest, clinical probability of CAD.

Determination of transmural, endocardial, and epicardial radial strain and strain rate from phase contrast MR velocity data.

To develop a method for computing radial strain (ε) and strain rate (SR) from phase contrast magnetic resonance (PCMR) myocardial tissue velocity data.

Absence of defects in SPECT thallium-201 myocardial images in patients with systemic hypertension and left ventricular hypertrophy

Hypertension is common in patients undergoing stress and delayed single-photon emission computed tomography (SPECT) thallium-201 myocardial perfusion imaging. Investigators have reported that patients with end-stage renal disease and left ventricular hypertrophy due to hypertension have diminished lateral/septal count ratios on stress and delayed imaging mimicking lateral myocardial infarction in approximately 35% of patients. Subsequently, hypertension has been cited as a frequent cause of thallium-201 artifacts. The purpose of this study was to compare myocardial SPECT thallium-201 distribution in a broader group of patients with left ventricular hypertrophy resulting from hypertension with normal file subjects in order to determine the prevalence of abnormal studies and to compare the lateral/septal count ratio. Average counts in all myocardial regions in the male study group (n = 16) were compared with those in the normal male file patients (n = 49), with particular attention to the lateral and septal walls. In the group of 16 men with hypertension and left ventricular hypertrophy, as a whole, the mean lateral/septal wall count ratio was 4.4% lower (1.09 +/- 0.07) than that in the normal file (1.14 +/- 0.07; p < 0.01). At 3-hour delay, the ratio was virtually the same in the study group (1.06 +/- 0.09) as in the normal file (1.08 +/- 0.06; p = NS). Most important, for clinical purposes no patient had a defect, defined as a lateral/septal count ratio > 2.0 SD below normal limits. All thallium-201 studies were interpreted as normal. In conclusion, myocardial thallium-201 distribution is normal in patients with left ventricular hypertrophy due to hypertension.

Automated region selection for analysis of dynamic cardiac SPECT data

Dynamic cardiac SPECT using Tc-99m labeled teboroxime can provide kinetic parameters (washin, washout) indicative of myocardial blood flow. A time-consuming and subjective step of the data analysis is drawing regions of interest to delineate blood pool and myocardial tissue regions. The time-activity curves of the regions are then used to estimate local kinetic parameters. In this work, the appropriate regions are found automatically, in a manner similar to that used for calculating maximum count circumferential profiles in conventional static cardiac studies. The drawbacks to applying standard static circumferential profile methods are the high noise level and high liver uptake common in dynamic teboroxime studies. Searching along each ray for maxima to locate the myocardium does not typically provide useful information. Here we propose an iterative scheme in which constraints are imposed on the radii searched along each ray. The constraints are based on the shape of the time-activity curves of the circumferential profile members and on an assumption that the short axis slices are approximately circular. The constraints eliminate outliers and help to reduce the effects of noise and liver activity. Kinetic parameter estimates from the automatically generated regions were comparable to estimates from manually selected regions in dynamic canine teboroxime studies.

Thromboembolism in Cancer Patients: Pathogenesis and Treatment

In this review we summarize the causes of cancer related thrombosis as well as modern treatment approaches. Malignancy as a risk factor for thromboembolism is becoming increasingly recognized by clinicians caring for these patients. The probability of thrombosis occurring in an individual patient is dependent on several factors, including accompanying medical problems, the type of cancer, the clinical stage, performance status, and the treatment modalities employed. Thrombophilia with a history of thromboembolism is important as well. The overall risk of thrombosis is sevenfold that of noncancer patients. Though much has been learned about the pathogenesis of cancer-related thrombosis, we are in fact just beginning to understand the cross-talk between cancer cells and their related microenvironment, and such investigations are likely to increase our knowledge of cancer-related thrombosis mechanisms. Research in these areas may also suggest new strategies for cancer prevention, metastasis suppression, and new treatments. Drugs used in cancer therapy are increasingly recognized to directly contribute to the thrombotic tendency. Few studies provide data on the optimal management of cancer patients with thrombosis. It has been learned that retreating with the same drug can be very hazardous. In general the approach to prevention of thrombosis is the same as for noncancer patients, recognizing that specific cancer types and stage can place a patient in a high-risk category. Initial coumadin therapy fails in a significant number of patients with cancer. Recognition of the cancer patients at highest risk for coumadin failure is challenging. Low-molecular-weight heparins appear to be more effective in such situations where coumadin is likely to fail or has failed, but these drugs are thought to be costlier. Newer agents such as Factor Xa inhibitors and TF inhibitors are currently under investigation and may be found useful in the management of cancer-related thrombosis.

Cross-Correlation Delay to Quantify Myocardial Dyssynchrony From Phase Contrast Magnetic Resonance (PCMR) Velocity Data

To apply cross‐correlation delay (XCD) analysis to myocardial phase contrast magnetic resonance (PCMR) tissue velocity data and to compare XCD to three established “time‐to‐peak” dyssynchrony parameters.